The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases

Eric J. Boren, Gurtej S. Cheema, Stanley M Naguwa, Aftab A. Ansari, M. Eric Gershwin

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Progressive multifocal leukoencephalopathy (PML) is a rare and devastating neurological disease with areas of demyelination in the central nervous system classically associated with profound imunosuppression. PML is caused by reactivation of latent JC virus, leading to the death of myelin-producing oligodendrocytes typically with a rapidly fatal outcome. Once seen primarily in severely immunosuppressed states including lymphoma, solid organ malignancies, and organ transplant recipients, PML became an AIDS-defining illness in the 1980s. PML has now emerged as a catastrophic illness in multiple sclerosis with biologic drug therapy (natalizumab) and reported in rheumatic diseases with and without biologic therapeutic agents. With current and future treatments that suppress and manipulate the immune system, there is risk for severe acute infections and reactivation of latent infections, such as JC virus reactivation leading to PML. It is critical, therefore, to proceed cautiously when immune system modification strategies are being evaluated for fear of unleashing undesirable or even fatal diseases. Fortunately this complication remains a rare event.

Original languageEnglish (US)
Pages (from-to)90-98
Number of pages9
JournalJournal of Autoimmunity
Volume30
Issue number1-2
DOIs
StatePublished - Feb 2008

Fingerprint

Progressive Multifocal Leukoencephalopathy
Rheumatic Diseases
JC Virus
Immune System
Catastrophic Illness
Biological Therapy
Fatal Outcome
Oligodendroglia
Biological Factors
Demyelinating Diseases
Myelin Sheath
Infection
Multiple Sclerosis
Fear
Lymphoma
Acquired Immunodeficiency Syndrome
Central Nervous System
Transplants
Drug Therapy
Therapeutics

Keywords

  • JC virus
  • Multiple sclerosis
  • Natalizumab (Tysabri)
  • Progressive multifocal leukoencephalopathy
  • Rheumatic disease
  • Rituximab (Rituxan)
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. / Boren, Eric J.; Cheema, Gurtej S.; Naguwa, Stanley M; Ansari, Aftab A.; Gershwin, M. Eric.

In: Journal of Autoimmunity, Vol. 30, No. 1-2, 02.2008, p. 90-98.

Research output: Contribution to journalArticle

@article{3c0afa5fea8544279d085b8fca1e339c,
title = "The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases",
abstract = "Progressive multifocal leukoencephalopathy (PML) is a rare and devastating neurological disease with areas of demyelination in the central nervous system classically associated with profound imunosuppression. PML is caused by reactivation of latent JC virus, leading to the death of myelin-producing oligodendrocytes typically with a rapidly fatal outcome. Once seen primarily in severely immunosuppressed states including lymphoma, solid organ malignancies, and organ transplant recipients, PML became an AIDS-defining illness in the 1980s. PML has now emerged as a catastrophic illness in multiple sclerosis with biologic drug therapy (natalizumab) and reported in rheumatic diseases with and without biologic therapeutic agents. With current and future treatments that suppress and manipulate the immune system, there is risk for severe acute infections and reactivation of latent infections, such as JC virus reactivation leading to PML. It is critical, therefore, to proceed cautiously when immune system modification strategies are being evaluated for fear of unleashing undesirable or even fatal diseases. Fortunately this complication remains a rare event.",
keywords = "JC virus, Multiple sclerosis, Natalizumab (Tysabri), Progressive multifocal leukoencephalopathy, Rheumatic disease, Rituximab (Rituxan), Systemic lupus erythematosus",
author = "Boren, {Eric J.} and Cheema, {Gurtej S.} and Naguwa, {Stanley M} and Ansari, {Aftab A.} and Gershwin, {M. Eric}",
year = "2008",
month = "2",
doi = "10.1016/j.jaut.2007.11.013",
language = "English (US)",
volume = "30",
pages = "90--98",
journal = "Journal of Autoimmunity",
issn = "0896-8411",
publisher = "Academic Press Inc.",
number = "1-2",

}

TY - JOUR

T1 - The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases

AU - Boren, Eric J.

AU - Cheema, Gurtej S.

AU - Naguwa, Stanley M

AU - Ansari, Aftab A.

AU - Gershwin, M. Eric

PY - 2008/2

Y1 - 2008/2

N2 - Progressive multifocal leukoencephalopathy (PML) is a rare and devastating neurological disease with areas of demyelination in the central nervous system classically associated with profound imunosuppression. PML is caused by reactivation of latent JC virus, leading to the death of myelin-producing oligodendrocytes typically with a rapidly fatal outcome. Once seen primarily in severely immunosuppressed states including lymphoma, solid organ malignancies, and organ transplant recipients, PML became an AIDS-defining illness in the 1980s. PML has now emerged as a catastrophic illness in multiple sclerosis with biologic drug therapy (natalizumab) and reported in rheumatic diseases with and without biologic therapeutic agents. With current and future treatments that suppress and manipulate the immune system, there is risk for severe acute infections and reactivation of latent infections, such as JC virus reactivation leading to PML. It is critical, therefore, to proceed cautiously when immune system modification strategies are being evaluated for fear of unleashing undesirable or even fatal diseases. Fortunately this complication remains a rare event.

AB - Progressive multifocal leukoencephalopathy (PML) is a rare and devastating neurological disease with areas of demyelination in the central nervous system classically associated with profound imunosuppression. PML is caused by reactivation of latent JC virus, leading to the death of myelin-producing oligodendrocytes typically with a rapidly fatal outcome. Once seen primarily in severely immunosuppressed states including lymphoma, solid organ malignancies, and organ transplant recipients, PML became an AIDS-defining illness in the 1980s. PML has now emerged as a catastrophic illness in multiple sclerosis with biologic drug therapy (natalizumab) and reported in rheumatic diseases with and without biologic therapeutic agents. With current and future treatments that suppress and manipulate the immune system, there is risk for severe acute infections and reactivation of latent infections, such as JC virus reactivation leading to PML. It is critical, therefore, to proceed cautiously when immune system modification strategies are being evaluated for fear of unleashing undesirable or even fatal diseases. Fortunately this complication remains a rare event.

KW - JC virus

KW - Multiple sclerosis

KW - Natalizumab (Tysabri)

KW - Progressive multifocal leukoencephalopathy

KW - Rheumatic disease

KW - Rituximab (Rituxan)

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=38049000341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049000341&partnerID=8YFLogxK

U2 - 10.1016/j.jaut.2007.11.013

DO - 10.1016/j.jaut.2007.11.013

M3 - Article

C2 - 18191544

AN - SCOPUS:38049000341

VL - 30

SP - 90

EP - 98

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

SN - 0896-8411

IS - 1-2

ER -